文献速递血液净化与透析肾移植

肾脏替代治疗患者抑郁症状的两步筛查:一项横断面分析

Two-step screening for depressive symptoms in patients treated with kidney replacement therapies: a cross-sectional analysis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

在加拿大多伦多开展横断面研究,纳入480例透析或肾移植成人,模拟以ESASr-D或PHQ-2为初筛、PROMIS-D为第二步的两步筛查,以PHQ-9为参照。PHQ-2≥1联合PROMIS-D≥53的灵敏度0.81、特异度0.84、NPV 0.95,且减少答题负担。

要点

  • PHQ-2≥1联合PROMIS-D≥53两步筛查灵敏度0.81、特异度0.84、NPV 0.95。
  • 基于PHQ-9,19%的患者有中度或重度抑郁症状。
  • 两步筛查可减少患者完成的题目数量。

核心结论

  • 以PHQ-2≥1为初筛、PROMIS-D≥53为第二步的两步筛查对肾脏替代治疗患者潜在显著抑郁症状识别具有良好灵敏度和特异度,且答题负担较低。
  • 筛查阳性患者仍需进一步临床评估以确立诊断。

研究设计与样本

  • 横断面研究,在加拿大安大略省多伦多开展,纳入成人肾移植受者或透析患者共480例。
  • 模拟多种两步筛查方案:ESASr-D或PHQ-2初筛超过界值者进入第二步PROMIS-D,以PHQ-9为参照评估筛查性能。

主要发现

  • 480例参与者中60%为男性,平均年龄55岁。
  • 基于PHQ-9,19%的患者有中度或重度抑郁症状。
  • PHQ-2≥1联合PROMIS-D≥53的两步筛查灵敏度0.81、特异度0.84、NPV 0.95。
  • 两步筛查减少患者完成的题目数量。

关键数值与推荐

  • PHQ-2评分≥1且PROMIS-D评分≥53为最佳两步筛查组合,灵敏度0.81、特异度0.84、NPV 0.95。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systematic screening for depressive symptoms may identify patients who may benefit from clinical assessment and psychosocial support. Here we assess a two-step screening using ultrabrief pre-screeners [Edmonton Symptom Assessment Survey-revised Depression item (ESASr-D) or Patient Health Questionnaire-2 (PHQ-2)] followed by the Patient-Reported Outcomes Measurement Information System Depression questionnaire (PROMIS-D) to identify depressive symptoms in patients on kidney replacement therapies. METHODS: We conducted a cross-sectional study of adults (kidney transplant recipients or treated with dialysis) in Toronto, ON, Canada. We simulated various two-step screening scenarios where only patients above a pre-screening cut-off score on the ESASr-D or PHQ-2 would move to step 2 (PROMIS-D). Screening performance was evaluated by sensitivity, specificity and positive and negative predictive values using the Patient Health Questionnaire-9 (PHQ-9) as the referent. The average number of items completed by patients in different scenarios was reported. RESULTS: Of 480 participants, 60% were male with a mean age of 55 years. Based on PHQ-9, 19% of patients had moderate or severe depressive symptoms. Pre-screening with a PHQ-2 score ≥1 combined with a PROMIS-D score of ≥53 provided the best two-step results (sensitivity 0.81, specificity 0.84, NPV 0.95). Two-step screening also reduces question burden. CONCLUSIONS: A two-step screening using a PHQ-2 score ≥1 followed by a PROMIS-D score ≥53 has good sensitivity and specificity for identifying potentially significant depressive symptoms among patients on kidney replacement therapies. This approach has lower question burden. Screened-in patients will need further clinical assessment to establish a diagnosis.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Dano S, Lan HH, Macanovic S, et al. Two-step screening for depressive symptoms in patients treated with kidney replacement therapies: a cross-sectional analysis. Nephrol Dial Transplant. 2023. PMID: 36095145. doi:10.1093/ndt/gfac262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。